FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.
All articles by James Nam, PharmD
Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk PCa
The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear.
High Body Mass Index May Predict Survival Outcomes in RCC
The association between obesity, age, and renal cell carcinoma prognosis requires additional investigation.
Relative Visceral Fat Indicates Mortality Risk for Women With RCC
An evaluation of patients with clear cell renal cell carcinoma revealed greater risk of death for female patients with high relative visceral fat area (rVFA), highlighting the significance of metabolic differences between men and women.
5α-Reductase Inhibitors Not Tied to High-Grade Prostate Cancer
A previous study showed that using 5-ARIs to treat benign prostate hyperplasia decreased the risk of low-grade PCa.
Fatigue Tied With Sorafenib, Sunitinib Use in Renal Cell Carcinoma
Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.
High Intakes of Teas, Peas, Soybeans May Increase Prostate Cancer Risk
An analysis of an intervention arm of the PLCO Cancer Screening Trial evaluated the risk of prostate cancer relative to dietary consumption of isoflavones, a dietary compound found in some plant foods.
Preop Aerobic Exercise May Improve Cystectomy Outcomes
A feasibility study involving 60 patients with bladder cancer sought to determine if preoperative vigorous cardiovascular activity would improve postsurgical outcomes.
Warfarin May Decrease Cancer Risk
For this population-based cohort study, researchers analyzed the health outcomes of 1,256,725 patients and separated them into warfarin- and non-warfarin-using subgroups.
Additions to Standard Care in High-Risk PCa May Up Survival
Findings from this comparative study indicate a favorable failure-free survival and progression-free survival with Standard of Care plus abiraterone acetate and prednisone.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...